title: [Magnetic resonance imaging of the brain in the monitoring of immune therapy of multiple sclerosis].
abstract: Magnetic resonance imaging of the brain is currently the most sensitive method in detecting the lesions caused by multiple sclerosis. Assessment of the immunological treatment response used in the treatment of multiple sclerosis should be based on the clinical picture and brain MRI. T2-, flair- and T1-biased images, gadolinium enhancement and assessment of atrophy are required for MRI monitoring. In the first-line immune therapy MRI is taken at 6 to 12 months after starting the drug therapy, in fingolimod therapy after 6 to 12 months and 1 to 2 years, respectively, and in alemtuzumab and natalizumab therapy after one and two years.
authors.forename: Irina
authors.initials: I
authors.lastname: Elovaara
authors.forename: Merja
authors.initials: M
authors.lastname: Soilu-Hänninen
authors.forename: Hanna
authors.initials: H
authors.lastname: Kuusisto
authors.forename: Juha
authors.initials: J
authors.lastname: Martola
authors.forename: Pentti
authors.initials: P
authors.lastname: Tienari
authors.forename: Markus
authors.initials: M
authors.lastname: Färkkilä
authors.forename: Anne M
authors.initials: AM
authors.lastname: Remes
mesh_terms: D000074323:Alemtuzumab; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D003287:Contrast Media; D000068876:Fingolimod Hydrochloride / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D007167:Immunotherapy; D008279:Magnetic Resonance Imaging / Q000379:methods*; D009103:Multiple Sclerosis / Q000276:immunology* / Q000628:therapy*; D000069442:Natalizumab / Q000627:therapeutic use
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003287:Contrast Media; D007166:Immunosuppressive Agents; D000069442:Natalizumab; D000074323:Alemtuzumab; D000068876:Fingolimod Hydrochloride